Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 2 randomized, open-label, controlled, parallel-arm study of Ampligen locally advanced pancreatic cancer

Trial Profile

Phase 2 randomized, open-label, controlled, parallel-arm study of Ampligen locally advanced pancreatic cancer

Status: Planning
Phase of Trial: Phase II

Latest Information Update: 28 Nov 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Rintatolimod (Primary)
  • Indications Carcinoma; Pancreatic cancer
  • Focus Therapeutic Use
  • Sponsors AIM ImmunoTech

Most Recent Events

  • 15 Nov 2023 According to an AIM ImmunoTech media release, the company expects to open European site in Q4 2023.
  • 15 Aug 2023 According to an AIM ImmunoTech media release, the company expects to enroll and dose first patient in this study in Q3 2023.
  • 12 Apr 2022 According to an AIM ImmunoTech media release, the company engaged Amarex Clinical Research LLC, CRO for conducting this study. The company plans to initiate this study in Q3 2022.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top